InvestorsHub Logo
Followers 218
Posts 15920
Boards Moderated 7
Alias Born 06/02/2007

Re: frenchbroad post# 401069

Friday, 12/29/2023 5:01:05 PM

Friday, December 29, 2023 5:01:05 PM

Post# of 402865

""Brilacidin has previously been tested in over 500 human subjects across multiple clinical indications where it has been shown to be efficacious and well-tolerated"



What a sad lapse in scientific writing. Indeed what a sad lapse in truthful writing.

Brilacidin has shown an unpleasant toxicity profile in every clinical study performed, with peripheral neuropathy and/or hypertensive spikes shown in the majority of subjects unfortunate enough to receive the drug candidate. Here's just one study that demonstrates that:



As for efficacy, in the clinical study in COVID-19 brilacidin was shown not only to add zero benefit to standard of care, it actually showed a clear trend towards delaying time to recovery, as well as adding toxicity that was unnecessary by definition (https://classic.clinicaltrials.gov/ct2/show/results/NCT04784897?term=brilacidin&draw=2&rank=2).

The authors of that piece have either failed to perform even a rudimentary minimum of literature review to substantiate their piece, or are very dishonest.

I hope it's the former although I suspect we all know who has influenced their research and that individual's unreasonable adherence to his "brainchild".
Bearish
Bearish

“What gets us into trouble is not what we don't know. It's what we know for sure that just ain't so.”

- Mark Twain

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News